Orzax's Production Power Nuvita İlaç Continued Its Rise in R&D 500
Nuvita İlaç, which carries out Orzax's production activities, continued its rise in the 2025 results of the Turkishtime Türkiye R&D 500 Survey. The company climbed 17 places to rank 231st in R&D spending, and 24 places to rank 41st in the number of R&D projects.
Nuvita İlaç, which carries out Orzax's production activities, continued its rise in the 2025 results of the Turkishtime Türkiye R&D 500 Survey. The company climbed 17 places to rank 231st in R&D spending, and 24 places to rank 41st in the number of R&D projects.
Nuvita İlaç increased its R&D investments by 53.8 percent in 2025, bringing them up to 84.8 million TL. The company thus maintained its place among Türkiye's top 250 companies with the highest R&D spending.
Entered the top 50 in R&D projects
The company also increased the number of R&D projects it carries out. Raising its project count from 38 to 49, Nuvita İlaç rose to 41st place this year from 65th place last year in the ranking.
With this result, Nuvita İlaç took its place among the top 50 companies in Türkiye carrying out the most R&D projects.
Nuvita İlaç R&D Manager Akif Emre Kavak stated that they view R&D efforts as one of the fundamental elements of sustainable growth, and said that they will continue to combine scientific know-how with production competencies.
Kavak stated that they are focused on developing new products and production solutions, enhancing their competencies in the field of strategic raw materials, and producing high value-added solutions for human health.
Advertisement
Ad Space728 × 90
